A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies
出版年份 2014 全文链接
标题
A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies
作者
关键词
B cell malignancies, GBR 401, Anti-CD19 monoclonal antibody, ADCC, Therapeutic antibody
出版物
Journal of Hematology & Oncology
Volume 7, Issue 1, Pages 33
出版商
Springer Nature
发表日期
2014-04-15
DOI
10.1186/1756-8722-7-33
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodies
- (2013) K Matlawska-Wasowska et al. LEUKEMIA
- GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present
- (2013) Delila J. Kern et al. LEUKEMIA & LYMPHOMA
- Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway
- (2012) J. Honeychurch et al. BLOOD
- Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities
- (2012) Shan Chung et al. mAbs
- An afucosylated anti-CD20 monoclonal antibody with greater antibody-dependent cellular cytotoxicity and B-cell depletion and lower complement-dependent cytotoxicity than rituximab
- (2012) John R. Gasdaska et al. MOLECULAR IMMUNOLOGY
- Anti-CD20 Antibody Therapy for B-Cell Lymphomas
- (2012) David G. Maloney NEW ENGLAND JOURNAL OF MEDICINE
- Enhanced ADCC Activity of Affinity Maturated and Fc-Engineered Mini-Antibodies Directed against the AML Stem Cell Antigen CD96
- (2012) Sahar Mohseni Nodehi et al. PLoS One
- Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma
- (2011) L. Alinari et al. BLOOD
- CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101
- (2011) M. Jak et al. BLOOD
- Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies
- (2011) W. Alduaij et al. BLOOD
- A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo
- (2011) Elizabeth Ward et al. BRITISH JOURNAL OF HAEMATOLOGY
- The predictive significance of CD20 expression in B-cell lymphomas
- (2011) Veronika Prevodnik et al. Diagnostic Pathology
- Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans
- (2011) Tsunehiro Mizushima et al. GENES TO CELLS
- The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden
- (2011) P. Boross et al. HAEMATOLOGICA
- Modern Therapy of Acute Lymphoblastic Leukemia
- (2011) Renato Bassan et al. JOURNAL OF CLINICAL ONCOLOGY
- Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc RIII and antibodies lacking core fucose
- (2011) C. Ferrara et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Novel Antibody-Based Therapies For Acute Lymphoblastic Leukemia
- (2011) D. Hoelzer Hematology-American Society of Hematology Education Program
- Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance
- (2010) C. Henry et al. BLOOD
- Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection
- (2010) S. A. Beers et al. BLOOD
- B-Cell Depletion In Vitro and In Vivo with an Afucosylated Anti-CD19 Antibody
- (2010) R. Herbst et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood
- (2009) Shigeru Iida et al. BMC CANCER
- A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies
- (2009) Pina M. Cardarelli et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Caspase-independent type III programmed cell death in chronic lymphocytic leukemia: the key role of the F-actin cytoskeleton
- (2009) S. Barbier et al. HAEMATOLOGICA
- The impact of Fc engineering on an anti-CD19 antibody: increased Fc receptor affinity enhances B-cell clearing in nonhuman primates
- (2008) J. Zalevsky et al. BLOOD
- Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia
- (2008) H. M. Horton et al. CANCER RESEARCH
- B cell–directed therapies for autoimmune disease and correlates of disease response and relapse
- (2008) Marc C. Levesque et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Anti-CD19 and anti-CD22 monoclonal antibodies increase the effectiveness of chemotherapy in Pre-B acute lymphoblastic leukemia cell lines
- (2007) C. Stanciu-Herrera et al. LEUKEMIA RESEARCH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started